Molina Arturo
Cougar Biotechnology, Los Angeles, California 90024, USA.
Annu Rev Med. 2008;59:237-50. doi: 10.1146/annurev.med.59.060906.220345.
The anti-CD20 monoclonal antibody rituximab, first approved for clinical use in 1997, has changed the standard of care for many patients with non-Hodgkin's lymphoma (NHL). Recent data from large randomized clinical trials confirm that the addition of rituximab to standard chemotherapy regimens (chemoimmunotherapy) improves both response rates and survival outcomes in patients with follicular NHL and diffuse large B cell lymphoma (DLBCL), the two most common subtypes of NHL. Population-based analyses have found substantial improvements in NHL survival over the past decade; studies indicate that rituximab has favorably altered the long-term prognosis of follicular NHL and DLBCL patients. This review discusses the clinical development of rituximab-based therapies for patients with low-grade or follicular NHL and newly diagnosed DLBCL, highlighting recent key randomized trials with a focus on survival outcomes.
抗CD20单克隆抗体利妥昔单抗于1997年首次获批用于临床，它改变了许多非霍奇金淋巴瘤（NHL）患者的治疗标准。大型随机临床试验的最新数据证实，在标准化疗方案（化疗免疫疗法）中加入利妥昔单抗可提高滤泡性NHL和弥漫性大B细胞淋巴瘤（DLBCL）患者的缓解率和生存结果，这两种是NHL最常见的亚型。基于人群的分析发现，在过去十年中NHL患者的生存率有了显著提高；研究表明，利妥昔单抗已改善了滤泡性NHL和DLBCL患者的长期预后。本综述讨论了基于利妥昔单抗的疗法在低度或滤泡性NHL以及新诊断的DLBCL患者中的临床进展，重点介绍了近期关键的随机试验及其生存结果。
